
A drug called erlotinib Tablets IP 150 mg is used to treat specific cancers. The active component, erlotinib, is a type of tyrosine kinase inhibitor that inhibits certain proteins that encourage the proliferation of cancer cells. Professionals in medicine give these oral tablets for diseases like pancreatic cancer and non-small cell lung cancer. Depending on the health of the patient and their medical history, the 150 mg dosage is intended for personalized treatment. To ensure safe and efficient use, it is crucial to stick to the recommended dosage and the healthcare provider's instructions.
The usage of Erlotinib Tablets IP 150 mg should only occur under the supervision and prescription of a licensed healthcare provider, despite the fact that they may have some advantages. For the best possible treatment results, continuous monitoring and follow-up are essential. Individual responses to the medicine may differ.
1. What is the purpose of erlotinib tablets IP 150 mg?
The main conditions that Erlotinib Tablets IP 150 mg are used to treat include non-small cell lung cancer (NSCLC) and pancreatic cancer that has metastasized to other organs.
2. How do IP 150 mg erlotinib tablets function?
The kinase inhibitor drug class of medicines includes erlotinib Tablets IP 150 mg. It functions by preventing an individual protein (epidermal growth factor receptor, or EGFR), which is in charge of the growth and division of cancer cells.
3. How do I take 150 mg Erlotinib Tablets IP?
Take the 150 mg Erlotinib Tablets IP exactly as directed by your physician. It is typically taken once daily with a full glass of water, on an empty stomach, at least an hour before or two hours after a meal. Based on your unique condition, your doctor will give you precise advice.
4. What negative effects might Erlotinib Tablets IP 150 mg have?
Rash, diarrhea, nausea, vomiting, loss of appetite, lethargy, and gastrointestinal problems are some of the side effects of erlotinib tablets IP 150 mg.
![]() |
BIOGEN INDIA
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |